Company
Ultromics
Advanced AI that flags HFpEF and cardiac amyloidosis from a single echo view.
Also known as Ultromics Ltd
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Oxford, United Kingdom
- Customers
- U.S. hospitals
- Legal name
- Ultromics Ltd
- ultromics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
Ultromics provides FDA-cleared, clinically validated AI to help identify patients with HFpEF and cardiac amyloidosis by analyzing routine echocardiograms within existing workflows, supporting the identification of two severely undiagnosed conditions.
Funding snapshot
- Total raised
- $55MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Undisclosed2025-12-17
Funding rounds
- Strategic Investment
- 2025-12-17
- Series C
- $55M2025-07-31, Company stated
Products
- Other
- EchoGo Amyloidosis
- Other
- EchoGo Heart Failure
Loading relationship preview